Oxcarbazepine
- Generic Name
- Oxcarbazepine
- Brand Names
- Oxtellar, Trileptal
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12N2O2
- CAS Number
- 28721-07-5
- Unique Ingredient Identifier
- VZI5B1W380
- Background
Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. It is a structural derivative of carbamazepine and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active...
- Indication
In the United States, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.
...
- Associated Conditions
- Partial-Onset Seizures
- Associated Therapies
- Monotherapy
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
- Conditions
- Interventions
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 14
- Registration Number
- NCT00900237
- Locations
- 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerpen, Antwerpen, Belgium
Oxcarbazepine 600 mg Tablets Under Fasting Conditions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 60
- Registration Number
- NCT00850174
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 120
- Registration Number
- NCT00849797
- Locations
- 🇨🇦
SFBC Anapharm, Montreal, Quebec, Canada
Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 54
- Registration Number
- NCT00637234
- Locations
- 🇩🇪
Isar-Amper-Klinikum gemeinnützige GmbH, Klinik Taufkirchen (Vils), Taufkirchen (Vils), Bayern, Germany
🇩🇪University of Cologne, Dept. of Psychiatry and Psychotherapy, Cologne, NRW, Germany
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 48
- Registration Number
- NCT00618046
- Locations
- 🇺🇸
Bio-Kinetics Clinical Applications, Inc ., Springfield, Missouri, United States
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 28
- Registration Number
- NCT00616863
- Locations
- 🇨🇦
MDS Pharma Services, Montreal, Quebec, Canada
Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 28
- Registration Number
- NCT00616681
- Locations
- 🇨🇦
MDS Pharma Services, Montreal, Quebec, Canada
Oxcarbazepine Versus Placebo in Childhood Autism
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2021-01-13
- Target Recruit Count
- 5
- Registration Number
- NCT00467753
- Locations
- 🇺🇸
Child and Adolescent Psychiatry at the University Behavioral Healthcare Building, UMDNJ-RWJMS, Piscataway, New Jersey, United States
Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
- Conditions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00275912
- Locations
- 🇷🇺
Russian State Medical University clinically based on Russian Pediatric Clinical Hospital, Moscow, Russian Federation
🇷🇺Regional Pediatric Clinical Hospital №1 EkaterinburgRegional Pediatric Clinical Hospital №1, Ekaterinburg, Russian Federation
🇷🇺Moscow Scientific Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russian Federation
Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures
- Conditions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2007-11-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00275925
- Locations
- 🇷🇺
Neurology and Neurosurgery Department of the Russian State Medical University, Moscow, Russian Federation
🇷🇺Neurology and Neurosurgery Department of the Moscow State Medico-stomatology University, Moscow, Russian Federation
🇷🇺Neurology Department of the Moscow region Research Institute named after M.F. Vladimirskiy, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.